Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-652 NSAID · 1 trial · 1 indication
Subject reported 24-hour average pain score measured by Visual Analogue Scale
| Arm | Type | Description |
|---|---|---|
| ABT-652 NSAID | EXPERIMENTAL | ABT-652 capsules -2 ABT-652 capsules twice daily (add-on) NSAID - as prescribed |
| Placebo NSAID | PLACEBO_COMPARATOR | Placebo - 2 placebo capsules twice daily NSAID - as prescribed |
| Name | Type | Description |
|---|---|---|
| ABT-652 NSAID | DRUG | ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed |
| Placebo NSAID | DRUG | Placebo - 2 placebo capsules twice daily NSAID- as prescribed |
Inclusion Criteria: * History of osteoarthritis (OA) of the knee joint and meeting American College of Rheumatology (ACR) Clinical and Radiographic criteria, * Currently taking nonsteroidal anti-inflammatory drugs (NSAIDs) and still experiencing pain as per the protocol requirements. * Willing to w...
ABT-652 NSAID is an investigational small molecule being studied for the treatment of osteoarthritis of the knee. It is intended for use in combination with a nonsteroidal anti-inflammatory drug (NSAID) to address osteoarthritis pain in adults. The drug is currently in Phase 2 clinical development and is not yet approved.
ABT-652 NSAID is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug for osteoarthritis of the knee.
ABT-652 NSAID is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug remains under evaluation for the treatment of osteoarthritis of the knee.
ABT-652 NSAID has one completed clinical trial registered under NCT01444365. This Phase 2 study evaluated the drug in combination with a nonsteroidal anti-inflammatory drug (NSAID) in 202 adults with osteoarthritis pain of the knee. The trial was randomized, double-blind, and placebo-controlled, conducted in the United States.
ABT-652 NSAID is a small molecule designed to be used in combination with a nonsteroidal anti-inflammatory drug (NSAID) for the treatment of osteoarthritis of the knee. The specific molecular target of ABT-652 has not been disclosed in available clinical trial information.